Astria Therapeutics, Inc.
ATXS
$4.04
$0.061.51%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -94.26M | -100.04M | -93.24M | -81.63M | -72.89M |
Total Depreciation and Amortization | -- | -- | -- | -- | -- |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 8.51M | 8.42M | 8.22M | 7.77M | 6.86M |
Change in Net Operating Assets | 4.54M | -2.46M | 4.64M | -420.00K | -2.41M |
Cash from Operations | -81.21M | -94.09M | -80.38M | -74.29M | -68.45M |
Capital Expenditure | -325.00K | -341.00K | -325.00K | -20.00K | -25.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -191.54M | -189.82M | -196.03M | -186.15M | 135.08M |
Cash from Investing | -191.86M | -190.16M | -196.35M | -186.17M | 135.05M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 157.20M | 245.18M | 229.99M | 230.17M | 88.40M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 157.20M | 245.18M | 229.99M | 230.17M | 88.40M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -115.87M | -39.07M | -46.75M | -30.29M | 155.01M |